Seikagaku entered into an exclusive agreement with Zimmer Biomet for U.S. distribution of VISCO-3™, a 3-injection hyaluronic acid-based viscosupplement for the treatment of knee osteoarthritis pain.
VISCO-3 received FDA Premarket Approval in 4Q15. Zimmer Biomet and Seikagaku have partnered on U.S. sales of Seikagaku's Gel-One® single-injection viscosupplement since 2012. Seikagaku's SUPARTZ FX® 5-injection treatment is marketed by Bioventus.
Sources: Seikagaku Corporation; FDA.gov; ORTHOWORLD Inc.
Seikagaku entered into an exclusive agreement with Zimmer Biomet for U.S. distribution of VISCO-3™, a 3-injection hyaluronic acid-based viscosupplement for the treatment of knee osteoarthritis pain. VISCO-3 received FDA Premarket Approval in 4Q15. Zimmer Biomet and Seikagaku have partnered on U.S. sales of...
Seikagaku entered into an exclusive agreement with Zimmer Biomet for U.S. distribution of VISCO-3™, a 3-injection hyaluronic acid-based viscosupplement for the treatment of knee osteoarthritis pain.
VISCO-3 received FDA Premarket Approval in 4Q15. Zimmer Biomet and Seikagaku have partnered on U.S. sales of Seikagaku's Gel-One® single-injection viscosupplement since 2012. Seikagaku's SUPARTZ FX® 5-injection treatment is marketed by Bioventus.
Sources: Seikagaku Corporation; FDA.gov; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.